eMC Medicine Guides  
The electronic Medicines Compendium (eMC) contains information about UK licensed medicines.
go to eMC homepage
Search for:  
  Advanced Search

Novartis Consumer Health
Wimblehurst Road, Horsham, West Sussex, RH12 5AB
Telephone: +44 (0)1403 210 211
Fax: +44 (0)1403 323 919
Medical Information Direct Line: +44 (0)1403 323 046
Medical Information e-mail: medicalaffairs.uk@novartis.com
Customer Care direct line: +44 (0)1403 218 111
Medical Information Fax: +44 (0)1403 324 024

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 08/08/2008
SPC Lypsyl Cold Sore Gel


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Lypsyl ® Cold Sore Gel


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Lidocaine hydrochloride 2.0% w/w

Zinc sulphate 1.0% w/w

Cetrimide 0.5% w/w

For excipients see 6.1


Go to top of the page
3. PHARMACEUTICAL FORM

Gel


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

For the symptomatic relief of cold sores.

Route of administration:

Topical.


Go to top of the page
4.2 Posology and method of administration

Adults and children over 12 years: Apply a small amount to the affected area with your fingertips 3-4 times daily.

Children under 12 years: Not recommended.


Go to top of the page
4.3 Contraindications

Patients with a known hypersensitivity to lidocaine hydrochloride, zinc sulphate or cetrimide should not use the product.

Contact with the eyes should be avoided.

Not recommended for children under 12 years.


Go to top of the page
4.4 Special warnings and precautions for use

For external use only.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

No known interactions with other drugs.


Go to top of the page
4.6 Pregnancy and lactation

None known.


Go to top of the page
4.7 Effects on ability to drive and use machines

None known.


Go to top of the page
4.8 Undesirable effects

Skin irritation and occasional sensitisation may occur.


Go to top of the page
4.9 Overdose

None stated.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Lidocaine hydrochloride is a local anaesthetic of the amide type which is widely used for local application to mucous membranes. It produces surface anaesthesia by diminishing or preventing the conduction of sensory nerve impulses.

Cetrimide is a quaternary ammonium disinfectant. As well as having emulsifying and detergent properties, it is active against gram-positive and some gram-negative organisms.

Zinc sulphate has astringent properties.


Go to top of the page
5.2 Pharmacokinetic properties

Lidocaine hydrochloride is effectively absorbed from mucous membranes.


Go to top of the page
5.3 Preclinical safety data

Not applicable.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Hydroxyethylmethylcellulose 3000

Polysorbate 20

Nonoxynol 9

Propylene glycol

Menthol

Purified water


Go to top of the page
6.2 Incompatibilities

None known.


Go to top of the page
6.3 Shelf life

36 months


Go to top of the page
6.4 Special precautions for storage

Do not store above 30°C.


Go to top of the page
6.5 Nature and contents of container

Laminated tube consisting of aluminium foil coated internally and externally with low density polyethylene or high density polyethylene.

Pack size: 3g


Go to top of the page
6.6 Special precautions for disposal and other handling

Medicines should be kept out of the reach of children.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Novartis Consumer Health UK Ltd

Wimblehurst Road

Horsham

West Sussex

RH12 5AB

Trading as Novartis Consumer Health


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 00030/0120


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

23 January 1991.


Go to top of the page
10. DATE OF REVISION OF THE TEXT

29 January 2003

Legal category: GSL



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/21079/SPC/


Active Ingredients/Generics

 
  cetrimide
  zinc sulphate monohydrate
  lidocaine hydrochloride